Last reviewed · How we verify
Sunitinib + Capecitabine
Sunitinib inhibits multiple receptor tyrosine kinases, including VEGFR, PDGFR, and c-KIT, while Capecitabine is a prodrug that is converted into 5-fluorouracil, a thymidylate synthase inhibitor.
Sunitinib inhibits multiple receptor tyrosine kinases, including VEGFR, PDGFR, and c-KIT, while Capecitabine is a prodrug that is converted into 5-fluorouracil, a thymidylate synthase inhibitor. Used for Renal cell carcinoma, Gastrointestinal stromal tumor.
At a glance
| Generic name | Sunitinib + Capecitabine |
|---|---|
| Sponsor | Pfizer |
| Drug class | tyrosine kinase inhibitor, antimetabolite |
| Target | VEGFR, PDGFR, c-KIT, thymidylate synthase |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Sunitinib's inhibition of VEGFR and PDGFR leads to anti-angiogenic effects, while its inhibition of c-KIT can affect tumor growth. Capecitabine's conversion to 5-fluorouracil results in the inhibition of thymidylate synthase, leading to DNA damage and cell death in rapidly dividing cancer cells.
Approved indications
- Renal cell carcinoma
- Gastrointestinal stromal tumor
Common side effects
- Hypertension
- Diarrhea
- Fatigue
- Nausea
- Hand-foot syndrome
Key clinical trials
- Pan Tumor Rollover Study (PHASE2)
- Sunitinib and Capecitabine for First Line Colon Cancer (PHASE2)
- Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial (PHASE1)
- A Study of BBI503 in Combination With Selected Anti-Cancer Therapeutics in Adult Patients With Advanced Cancer (PHASE1)
- Participatory Research for Fine-tuning of a 2.0 System to Optimise Home Management of Oral Cancer Therapies. (NA)
- Capecitabine With or Without Sunitinib Malate as First-Line Therapy in Treating Patients With Metastatic Cancer of the Esophagus or Gastroesophageal Junction (PHASE2)
- Sunitinib Malate and Capecitabine in Treating Patients With Unresectable or Metastatic Liver Cancer (PHASE2)
- Brain Mets - Capecitabine Plus Sunitinib and WBRT (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |